3.2 Grading

3.2 Grading

Grading is a critical element in treatment planning and should be clearly documented in the patient’s medical record. High-grade gliomas are classified as high-grade tumours.

Grading for high-grade gliomas involves both:

  • neuroimaging with MRI +/– CT
  • histological testing.

Genetic testing of the tumour should be conducted where relevant to determine appropriate treatment options. The following genetic tests may benefit patients with high-grade gliomas:

  • IDH1/IDH2 mutation
  • 1p/19q codeletion
  • MGMT methylation
  • TERT promoter methylation (EMSO 2017)
  • EGFR amplification or mutation
  • ATRX mutation.
More information

Visit the Cancer Institute New South Wales website for information about understanding the stages of cancer.